Invivyd Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Invivyd Inc 's ROA in the second quarter of 2026?
Invivyd Inc recorded a cumulative net loss of $-107 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -49.04%.

However, within the Healthcare sector 559 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3810, from total ROA ranking in the first quarter of 2026 at 4353.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	152.54 %	133.02 %	114.32 %	-14.13 %	-51.13 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-107	-78	-52	-60	-110
Return On Assets (TTM)	-49.04 %	-41.76 %	-34.68 %	-52.32 %	-91.71 %
IVVD's Total Ranking	# 3810	# 4353	# 4038	# 4411	# 4521
Total Assets (TTM) in million	219	242	277	138	87
Seq. Total Assets Change	-9.46 %	-12.69 %	100.6 %	59.25 %	-16.45 %
Seq. Net Income Change	-	-	-	-	-

IVVD's 5 Years Annual ROA >> Back to IVVD Management Effectiveness >> Compare IVVD ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 78
Sector	# 560
Overall	# 3883

Return On Assets Statistics
High	Average	Low
-17.81 %	-63.12 %	-114.88 %
(Mar 31 2022)		(Sep 30 2024)

News about Invivyd Inc Return on Assets ROA

Invivyd Applauds FDAs Forward-Thinking Approach to COVID Vaccine Efficacy as It Defends Against Evolving Variants with PEMGARDA,

Invivyd s Strong Stand Against Evolving COVID-19 Challenges and FDA s Progressive StepsIntroductionAs the landscape of COVID-19 continues to evolve with the emergence of new variants, companies and regulators alike must navigate the complexities of vaccine efficacy and therapeutic interventions. Invivyd, Inc. a biotechnology firm focused on developing monoclonal antibodies, has recently received attention for its commendation of the FDA s proactive approach toward understanding contemporary COVID-19 vaccination booster efficacy. This article outlines essential insights from Invivyd’s recent communications and the implications for ongoing COVID-19 management.FDA’s Acknowledgment of Vaccine Efficacy GapsOn May 20, 2025, the FDA, led by its new leadership, made notable strides in addressing uncertainties surrounding the efficacy of COVID-19 vaccine boosters. Invivyd commended the FDA’s timely recognition of gaps in the modern understanding of vaccine efficacy, emphasizing the need for evidence-based solutions in its publication

Financial Statements
Invivyd Inc 's Assets	$ 219 million	IVVD's Balance sheet
Invivyd Inc 's Income	$ -44 million	Quarterly IVVD's Income Statement
IVVD's Income by Division		See IVVD's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	114.32 %	-43.53 %	-39.98 %	-38.53 %	-
Total Assets in million	277	129	229	381	620
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-52	-170	-199	-241	-227
Annual Return On Assets	-18.96 %	-131.53 %	-86.83 %	-63.3 %	-36.57 %

IVVD's 5 Years Annual ROA >> Back to IVVD Management Effectiveness >> Compare IVVD ROA to its Competitors

More Return On Assets Ratios
IVVD's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
IVVD's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for IVVD's Competitors
Subscribers only: Roa for Invivyd Inc 's Suppliers
Subscribers only: Return On Assets for IVVD's Customers

You may also want to know
IVVD's Roi	IVVD's Inventory Turnover Ratio	IVVD's Growth Rates	IVVD's Dividend Comparisons
	IVVD's Profitability Ratios	IVVD's Asset Turnover Ratio	IVVD's Dividend Growth
IVVD's Roe	IVVD's Valuation Ratios	IVVD's Financial Strength Ratios	IVVD's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T18:19:16+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.